End-of-day quote
Other stock markets
|
||
- USD | - |
Apr. 09 | Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday | MT |
Apr. 09 | Alkermes Says Potential Narcolepsy Drug Improves Wakefulness in Phase 1b Study | MT |
Financials (USD)
Sales 2024 * | 1.52B | Sales 2025 * | 1.53B | Capitalization | 4.07B |
---|---|---|---|---|---|
Net income 2024 * | 352M | Net income 2025 * | 331M | EV / Sales 2024 * | 2.16 x |
Net cash position 2024 * | 791M | Net cash position 2025 * | 1.17B | EV / Sales 2025 * | 1.9 x |
P/E ratio 2024 * |
11.8
x | P/E ratio 2025 * |
13
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.59% |
Latest transcript on ALKERMES
Managers | Title | Age | Since |
---|---|---|---|
Richard Pops
CEO | Chief Executive Officer | 62 | 91-01-31 |
Blair Jackson
DFI | Director of Finance/CFO | 51 | 98-12-31 |
Shane Cooke
PSD | President | 61 | 11-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Pops
CEO | Chief Executive Officer | 62 | 91-01-31 |
Nancy Snyderman
BRD | Director/Board Member | 72 | 16-05-25 |
Brian McKeon
BRD | Director/Board Member | 61 | 20-12-09 |
1st Jan change | Capi. | |
---|---|---|
-0.02% | 42.11B | |
+46.11% | 40.08B | |
+5.04% | 40B | |
-11.32% | 26.87B | |
+5.25% | 24.58B | |
-23.83% | 18.44B | |
-1.62% | 11.94B | |
+22.75% | 11.66B | |
+6.44% | 11.01B |